May 10th 2024
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Patient Medical Group Continuity and Healthcare Utilization
Patients who often change medical groups have the highest healthcare costs. The improved coordination of an accountable care organization may reduce those costs.
Read More
Role of Pharmaceuticals in Value-Based Healthcare: A Framework for Success
A framework for the role of pharmaceuticals in value-based healthcare, practical examples from organizations that have made the transition, and implementation considerations.
Read More